Compared with metastatic tumors, primary breast cancers have more TILs and higher PD-L1 expression (60, 158), both of which are predictive of response to immunotherapy (2, 25, 136), leading to the hypothesis that ICB could have a more impactful role in the neoadjuvant setting. This evidence concerns the gene CD274 and breast carcinoma.